Osteoporosis after menopause is a growing public health concern that impacts bone health. It characterised by weak and fracture prone bones. Women are nearly four times likely as men to be affected. The goal improve proper prosthodontic therapy so residual ridge resorption reduced. main alveolar tooth loss or movement, which osteoporotic women three more sensitive than those without condition. ...

Recent trials of postmenopausal hormone therapy have shown lack of cardiovascular benefit or possible harm among women with and without underlying cardiovascular disease [1-7] . Despite a favorable impact on several cardiovascular risk markers, hormone therapy is thus not recommended for the primary or secondary prevention of cardiovascular disease. [8] Although alternatives are available, horm...

Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between Zol and risedronate for ne...

Objectives: Development and differentiation of osteoclasts are regulated by three factors which belong to the family of tumor necrosis factor: RANK, RANKL, OPG. Interaction disorders of the RANKL/RANK/OPG system can be an element of the etiopathogenesis of postmenopausal osteoporosis. Aim of the study: To examine the frequency of alleles and genotypes of four polymorphisms: !163 A > G, !245 T >...